Negotiation of contract for supply of berubicin by CNS Pharmaceuticals Inc.
23.01.2023
A contract for supply of berubicin to the Pomeranian Medical University was signed on 21 November 2022, capping months of preparations and negotiations between CNS Pharmaceuticals, Inc. and the university.
Our law firm’s representation of CNS Pharmaceuticals, Inc. in this project was coordinated by Joanna Krakowiak and supervised by Izabela Zielińska-Barłożek, and involved the multidisciplinary team of Anna Prigan, Dr Monika A. Górska, Dr Joanna Prokurat, Jakub Macek and Oliwia Kruczyńska.
Berubicin is a medicinal substance being studied for use in oncology, in particular for treatment of in the brain glioblastoma multiforme (GBM), as well as other conditions such as central nervous system lymphomas.
CNS Pharmaceuticals, Inc. is a biotech firm based in the United States involved in research into the use of berubicin for treatment of the most aggressive cancers of the brain and development of innovative oncology therapies.
The Pomeranian Medical University in Szczecin is one of the leading oncology centres in Poland.
The project will be implemented in the form of a non-commercial clinical trial financed by the Polish Medical Research Agency.